Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income remains negative
Q3 FY2026 operating income was -$663.71M, compared with -$14.53M a year earlier. Trailing-twelve-month operating income was -$697.72M.
Context
- Operating income amounted to 15.7% of revenue in FY2025, down 50.2 pp from a year earlier.
- Operating income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 6 analysts of -$634.41M (-793.9%) for the fiscal year ending Dec 2026, a slowdown from the +41.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$663.71M-3233.9% QoQ
- Last fiscal yearDec 2025
- -$70.97M+41.1% YoY
- LTMSep 2026
- -$697.72M-698.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4468.2% | -36.9% | +4431.3 pp |
| 1 year | +41.1% | -793.9% | -835.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (70.97M) USD
- Year-over-year change
- +41.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (70.97M) | +41.1% |
| FY2024 | 2024-12-31 | (120.57M) | +15.8% |
| FY2023 | 2023-12-31 | (143.16M) | -128.3% |
| FY2022 | 2022-12-31 | (62.71M) | -415.9% |
| FY2021 | 2021-12-31 | (12.16M) | — |
Operating Income vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 operating income of -$697.72M is the lowest of the 6 companies compared; the peer median is -$2.32M.
- Its year-over-year change of -698.2% is the lowest of 5, against a peer median of +111.9%.
- Operating income amounts to 102.3% of revenue for TARS, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $34.25M | +139.9% | — | 7.4% | |
| LTM Mar 2026 | $28.12M | +522.3% | +172.0% | 10.5% | |
| LTM Mar 2026 | -$2.32M | +83.8% | — | 12.6% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$6.72M | — | — | — |
| LTM Mar 2026 | -$13.52M | +75.6% | — | 36.4% | |
| LTM Sep 2026 | -$697.72M | -698.2% | — | 102.3% | |
| Peer median (excluding TARS) | -$2.32M | +111.9% | +172.0% | 11.5% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M |
| Cost of Revenue | 2.08M | 955K | 1.59M | 12.83M | 30.68M |
| Gross Profit | 54.95M | 24.86M | 15.85M | 170.13M | 420.68M |
| Gross Margin | 96.4% | 96.3% | 90.9% | 93.0% | 93.2% |
| Research & Development | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M |
| Selling, General & Admin | 25.4M | 44.95M | 108.7M | 237.31M | 427.32M |
| Operating Expenses | 67.11M | 87.57M | 159.01M | 290.7M | 491.65M |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| EBITDA | (13.46M) | (59.71M) | (131.67M) | (106.48M) | (53.61M) |
| EBITDA Margin | -23.6% | -231.3% | -754.7% | -58.2% | -11.9% |
| Operating Income | (12.16M) | (62.71M) | (143.16M) | (120.57M) | (70.97M) |
| Operating Margin | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Interest Income | 36K | 3.5M | 10.34M | 15.01M | 15.75M |
| Interest Expense | 0 | 2.06M | 3.23M | 7.45M | 8.94M |
| Other Income / Expenses | (1.62M) | 617K | 7.27M | 5.02M | 6.61M |
| Income Before Tax | (13.77M) | (62.1M) | (135.89M) | (115.55M) | (64.36M) |
| Pre-Tax Margin | -24.1% | -240.5% | -778.9% | -63.2% | -14.3% |
| Income Tax Expense | 55K | (4K) | 0 | 0 | 2.06M |
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Net Margin | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| EPS (Basic) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| EPS (Diluted) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| Weighted Avg Shares | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
| Weighted Avg Shares (Diluted) | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.